Ashland ASH Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Intermediates And Solvents | $35M-5.4% | $31M-6.1% | $33M-8.3% | $33M-8.3% | $37M-7.5% | |
| Life Sciences | $172M0.0% | $139M+3.7% | $173M-10.4% | $162M-16.9% | $172M-22.5% | |
| Personal Care And Household | $150M+2.7% | $123M-8.2% | $151M-6.2% | $147M-16.0% | $146M-13.6% | |
| Specialty Additives | $134M0.0% | $102M-11.3% | $131M-8.4% | $131M-12.7% | $134M-14.6% | |
| Cost Of Revenue by Business | ||||||
| Intermediates And Solvents | $29M-21.6% | $29M+3.6% | —— | —— | $37M+38.3% | |
| Life Sciences | $109M-6.8% | $94M+3.3% | —— | —— | $117M-9.1% | |
| Personal Care And Household | $88M+7.3% | $79M-9.2% | —— | —— | $82M-17.6% | |
| Specialty Additives | $118M+11.3% | $88M-11.1% | —— | —— | $106M-18.8% | |
| Income Loss On Divestitutres Net by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $0— | $0— | —— | —— | $0— | |
| Personal Care And Household | $0— | $0— | —— | —— | $0— | |
| Specialty Additives | $0— | $0— | —— | —— | $0— | |
| Unallocated And Other | -$0-100% | $2M+101% | —— | —— | $18M— | |
| Operating Income by Business | ||||||
| Intermediates And Solvents | $4M+500% | $0-100% | $2M-71.4% | $4M-33.3% | -$1M-111% | |
| Life Sciences | $35M+25.0% | $17M+21.4% | —— | -$343M-898% | $28M-44.0% | |
| Personal Care And Household | $27M-3.6% | $11M0.0% | $26M+85.7% | $25M-19.4% | $28M+12.0% | |
| Specialty Additives | -$7M-200% | -$8M-60.0% | $0— | -$345M-3,550% | $7M+139% | |
| Unallocated And Other | -$20M-81.8% | -$26M+87.1% | -$11M+73.2% | -$49M+67.5% | -$11M+75.6% | |
| Selling General And Administrative Expense by Business | ||||||
| Intermediates And Solvents | $2M+100% | $2M0.0% | —— | —— | $1M-42.9% | |
| Life Sciences | $20M+5.3% | $20M0.0% | —— | —— | $19M-14.6% | |
| Personal Care And Household | $21M0.0% | $20M-4.8% | —— | —— | $21M-11.6% | |
| Specialty Additives | $17M+13.3% | $16M0.0% | —— | —— | $15M-1.6% | |
| Unallocated And Other | $19M-34.5% | $28M+47.4% | —— | —— | $29M-23.7% | |
| Earnings Before Interest Tax Depreciation And Amortization by Business | ||||||
| Intermediates And Solvents | $5M+150% | $1M-83.3% | $5M-50.0% | $7M-22.2% | $2M-83.3% | |
| Life Sciences | $49M-9.3% | $31M+10.7% | —— | -$321M-653% | $54M-18.2% | |
| Personal Care And Household | $42M-2.3% | $26M-10.3% | $42M+23.5% | $40M-21.6% | $43M-4.4% | |
| Specialty Additives | $8M-65.2% | $10M-9.1% | $0-100% | -$309M-1,036% | $23M-11.5% | |
| Unallocated And Other | -$20M-81.8% | -$26M+87.1% | -$11M+73.2% | -$49M+67.5% | -$11M+75.6% | |
| Total Assets by Business | ||||||
| Intermediates And Solvents | $107M-10.1% | $110M-11.3% | $116M-8.7% | $118M-4.8% | $119M-11.9% | |
| Life Sciences | $1.46B-22.4% | $1.46B-19.5% | $1.5B-15.7% | $1.53B-13.6% | $1.88B-2.0% | |
| Personal Care And Household | $714M+1.7% | $723M+0.8% | $751M-20.9% | $699M-27.9% | $702M-28.5% | |
| Specialty Additives | $988M-27.1% | $990M-25.2% | $1.02B-32.7% | $1.05B-30.1% | $1.36B-11.2% | |
| Unallocated And Other | $1.24B+4.6% | $1.23B-1.4% | $1.23B-3.8% | $1.23B-11.2% | $1.18B-15.0% | |
| Research And Development Expense by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $3M-25.0% | $4M0.0% | —— | —— | $4M+6.7% | |
| Personal Care And Household | $6M-14.3% | $5M-16.7% | —— | —— | $7M+7.7% | |
| Specialty Additives | $4M+33.3% | $3M0.0% | —— | —— | $3M+9.1% | |
| Unallocated And Other | $1M— | $1M— | —— | —— | $0-100% | |
| Income Loss From Equity Method Investments And Other Income Expense by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $0— | $0— | —— | —— | $0— | |
| Personal Care And Household | $0— | $1M0.0% | —— | —— | $0— | |
| Specialty Additives | $0— | $0— | —— | —— | $0— | |
| Unallocated And Other | $0— | $0— | —— | —— | $0-100% | |
| PP&E (Net) by Business | ||||||
| Intermediates And Solvents | $30M— | $30M— | $30M-21.1% | —— | —— | |
| Life Sciences | $468M— | $477M— | $481M+15.9% | —— | —— | |
| Personal Care And Household | $95M— | $97M— | $101M-30.8% | —— | —— | |
| Specialty Additives | $468M— | $473M— | $484M-19.7% | —— | —— | |
| Unallocated And Other | $102M— | $104M— | $105M+4.0% | —— | —— | |
| Adjustment For Amortization by Business | ||||||
| Intermediates And Solvents | $0— | $0— | $1M+200% | $0— | $0— | |
| Life Sciences | $5M+25.0% | $5M0.0% | $5M0.0% | $5M-16.7% | $4M-20.0% | |
| Personal Care And Household | $8M0.0% | $8M-20.0% | $9M-18.2% | $8M-20.0% | $8M-27.3% | |
| Specialty Additives | $2M-33.3% | $2M0.0% | $2M0.0% | $2M-33.3% | $3M-25.0% | |
| Unallocated And Other | $0— | $0— | —— | —— | $0— | |
| Depreciation by Business | ||||||
| Intermediates And Solvents | $1M-66.7% | $1M-66.7% | $3M-25.0% | $3M0.0% | $3M0.0% | |
| Life Sciences | $9M-59.1% | $9M0.0% | $9M0.0% | $17M+88.9% | $22M+100% | |
| Personal Care And Household | $7M0.0% | $7M-12.5% | $7M-22.2% | $7M-30.0% | $7M-22.2% | |
| Specialty Additives | $13M0.0% | $16M+14.3% | $15M+7.1% | $34M+70.0% | $13M-67.5% | |
| Unallocated And Other | $0— | $0— | —— | —— | $0— | |
| Goodwill by Business | ||||||
| Life Sciences | $462M-42.8% | $467M-41.1% | $466M-43.3% | $466M-42.2% | $807M-2.8% | |
| Specialty Additives | $112M-73.7% | $113M-72.9% | $112M-74.2% | $112M-73.6% | $426M0.0% | |
| Goodwill Impaired Accumulated Impairment Loss by Business | ||||||
| Life Sciences | $375M— | $375M— | $375M— | $375M— | —— | |
| Specialty Additives | $505M+190% | $505M+190% | $505M+190% | $505M+190% | $174M0.0% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Life Sciences | -$5M— | $1M+103% | —— | $34M— | —— | |
| Specialty Additives | -$1M— | $1M+106% | —— | $17M— | —— | |
| Concentration Risk % by Product | ||||||
| Cellulosics And Polyvinylpyrrolidones | 64%+1.0pp | 65%+2.0pp | —— | 65%+8.0pp | 63%— | |
| Cellulosics | 41%+3.0pp | 39%+1.0pp | —— | 40%+4.0pp | 38%— | |
| Polyvinylpyrrolidones | 23%-2.0pp | 26%+1.0pp | —— | 25%+4.0pp | 25%— | |
| Revenue by Geography | ||||||
| Asia Pacific | $125M+4.2% | $110M-3.5% | $125M-10.1% | $118M-13.9% | $120M-10.4% | |
| Europe | $180M-1.1% | $132M-1.5% | $171M-5.0% | $176M-8.3% | $182M-13.3% | |
| Latin America And Other | $48M+6.7% | $41M-2.4% | $55M+10.0% | $45M-4.3% | $45M-15.1% | |
| North America | $138M-2.8% | $112M-11.1% | $137M-16.5% | $134M-25.6% | $142M-25.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ashland break its business down?
- Ashland (ASH) reports revenue by business across 4 parts — Intermediates And Solvents, Life Sciences, Personal Care And Household and Specialty Additives. Each is extracted from the segment footnotes and tracked over time.
- Where does Ashland's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ashland's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
